Enabling the Nervous System to Repair Itself
At NervGen, we are restoring life’s potential by developing first-in-class neuroreparative therapies that target the biological barriers to neural repair, with a growing pipeline led by NVG-291.
Born from a breakthrough. Backed by perseverance.
Dr. Jerry Silver spent decades challenging the belief that the nervous system was incapable of repair. His discoveries redefined the world of possibility.
NervGen exists at the intersection of personal experience and scientific discovery, built upon the foundation of Dr. Silver, the perseverance of Harold Punnett, and an unwavering mission to transform the lives of individuals living with spinal cord injury and nervous system damage.
NVG-291: A First-in-Class Approach to Redefining Recovery
NVG-291 is a 35 amino acid peptide administered as a daily subcutaneous injection, targeting chondroitin sulfate proteoglycans (CSPGs), the biological barriers preventing endogenous nervous system repair.
Who We Do This For
NervGen was born from a family’s personal experience. That origin is not just our history, it is our compass. Everything we do, from the design of our clinical trials to how we communicate our progress, is guided by the individuals, families, and communities we seek to serve.
RESTORE: A Registrational Trial of NVG-291
We are preparing to initiate RESTORE, a registrational clinical trial evaluating 12 weeks of daily subcutaneous treatment with NVG-291 in individuals living with chronic spinal cord injury. The primary endpoint is GRASSP Quantitative Prehension, a measure of functional hand use.
RESTORE: A Registrational Trial of NVG-291
We are preparing to evaluate NVG-291 in RESTORE, our registrational clinical trial evaluating 12 weeks of daily subcutaneous treatment with NVG-291 in individuals living with chronic spinal cord injury between one and ten years post-injury. The primary endpoint of RESTORE is GRASSP Quantitative Prehension, a measure of functional hand use.
